Early Use of Zoledronic Acid (Zometa) in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated [...]
Our Right To Die – An Unfair Media Circus that Never Should Have Happened
Today, I am going to make a little change in my post. Instead of discussing additional ASCO Conference abstracts of interest to men with advanced prostate cancer (I will come back to them in short [...]
From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).
Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the [...]
FROM THE 2013 ASCO GU CONFERENCE –CHEMOTHERAPY AND THE USE ANTICOAGULANTS INCREASE PROSTATE CANCER SURVIVAL RATES
Another interesting research abstract presented at the Genitourinary Cancers Symposium in Orlando Florida this month found that men with prostate cancer who were on chemotherapy who had also received anticoagulant (blood-thinners) medications experienced improved overall [...]
More From the 2013 ASCO GU Conference – An Updated Analysis of the Phase III Randomized Trial (ALSYMPCA) of Radium-223 dichloride (Ra-223)
Ra-223 is an investigational alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range alpha-particles. The recently completed phase 3, double-blind, randomized, multinational ALSYMPCA study showed that Ra-223 significantly improved over all survival (OS) in CRPC men [...]
From the 2013 Genitourinary Cancers Symposium – An Update of the Abiraterone Acetate (Zytiga) with Prednisone Clinical Trial
At the recent 2013 2013 Genitourinary Cancers Symposium there was an abstract presented that updated data from the COU-AA-302 clinical trial of Abiraterone Acetate (Zytiga) with prednisone. The updated data confirms that Zytiga with prednisone [...]